J&J seeks expanded Zytiga label
13:33 EDT 15 Jun 2012 | BioCentury
Johnson & Johnson (NYSE:JNJ) submitted regulatory applications to FDA and EMA for Zytiga abiraterone acetate to treat chemotherapy-naive patients with metastatic castration-resistant prostate cancer (CRPC) who are asymptomatic or mildly asymptomatic..
Original Article: J&J seeks expanded Zytiga label
More From BioPortfolio on "J&J seeks expanded Zytiga label"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
